The standard KLOW dose for women remains 3.2 mg per injection: 2 mg GHK-Cu plus 0.4 mg each of BPC-157, TB-4, and KPV
The trial demonstrated that once-weekly tirzepatide 10 mg and 15 mg offered substantial and clinically meaningful bodyweight reduction, with a safety profile similar to other therapies for weight management using incretin-based approaches
Month two is also when side effects tend to peak
[16] Sharma A, Tiwari M, Gupta A, Pandey AN, Yadav PK, Chaube SK
The MAO enzymes play an essential role in maintaining the appropriate amount of dopamine, serotonin, norepinephrine, and epinephrine
So maybe if enough people are on these drugs with enough effect, you could start seeing a decrease in the number of patients with the weight qualification to now meet that diagnosis if they were going to be a new patient